Beam Therapeutics annual net income
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics Net Income Growth & History (BEAM)
Beam Therapeutics's net income was −$80.0M for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$80.0M | $296.8M | — |
| 2024 | 2024-12-31 | −$376.7M | −$244.2M | — |
| 2023 | 2023-12-31 | −$132.5M | $156.6M | — |
| 2022 | 2022-12-31 | −$289.1M | $81.5M | — |
| 2021 | 2021-12-31 | −$370.6M | −$176.0M | — |
| 2020 | 2020-12-31 | −$194.6M | −$116.3M | — |
| 2019 | 2019-12-31 | −$78.3M | — | — |
Beam Therapeutics quarterly net income
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$122.7M | −$20.5M | — |
| Q1 2026 | 2026-03-31 | −$94.3M | $14.0M | — |
| Q4 2025 | 2025-12-31 | $243.2M | $333.6M | — |
| Q3 2025 | 2025-09-30 | −$112.7M | −$16.1M | — |
| Q2 2025 | 2025-06-30 | −$102.1M | −$11.1M | — |
| Q1 2025 | 2025-03-31 | −$108.3M | −$9.7M | — |
| Q4 2024 | 2024-12-31 | −$90.4M | −$233.2M | — |
| Q3 2024 | 2024-09-30 | −$96.7M | −$580,000 | — |
| Q2 2024 | 2024-06-30 | −$91.1M | −$8.3M | — |
| Q1 2024 | 2024-03-31 | −$98.7M | −$2.2M | — |
| Q4 2023 | 2023-12-31 | $142.8M | $181.1M | — |
| Q3 2023 | 2023-09-30 | −$96.1M | $13.5M | — |
| Q2 2023 | 2023-06-30 | −$82.8M | −$10.8M | — |
| Q1 2023 | 2023-03-31 | −$96.5M | −$27.2M | — |
| Q4 2022 | 2022-12-31 | −$38.3M | $26.4M | — |
| Q3 2022 | 2022-09-30 | −$109.6M | −$81.5M | — |
| Q2 2022 | 2022-06-30 | −$72.0M | $4.3M | — |
| Q1 2022 | 2022-03-31 | −$69.2M | $132.3M | — |
| Q4 2021 | 2021-12-31 | −$64.7M | $30.8M | — |
| Q3 2021 | 2021-09-30 | −$28.1M | $6.3M | — |
| Q2 2021 | 2021-06-30 | −$76.3M | −$42.0M | — |
| Q1 2021 | 2021-03-31 | −$201.6M | −$171.1M | — |
| Q4 2020 | 2020-12-31 | −$95.5M | −$67.6M | — |
| Q3 2020 | 2020-09-30 | −$34.5M | −$15.4M | — |
| Q2 2020 | 2020-06-30 | −$34.2M | −$16.4M | — |
| Q1 2020 | 2020-03-31 | −$30.5M | −$16.8M | — |
| Q4 2019 | 2019-12-31 | −$27.9M | — | — |
| Q3 2019 | 2019-09-30 | −$19.0M | — | — |
| Q2 2019 | 2019-06-30 | −$17.9M | — | — |
| Q1 2019 | 2019-03-31 | −$13.6M | — | — |
Beam Therapeutics net income trends
Over the last five fiscal years, Beam Therapeutics's net income increased from −$194.6M to −$80.0M, a change of $114.6M. The latest reported quarter, Q2 2026, shows −$122.7M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...